Topline data expected as early as mid-2025 - SOUTH SAN FRANCISCO, Calif., March 11, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced the initiation of a Phase 1, open label, dose ...
Stephen Krahling was a published cancer researcher when vaccine maker Merck brought him on board as a virologist in 1999. That’s when he says he found himself embroiled in an all-hands-on-deck ...
Martin Makary, President Donald Trump's nominee to run the U.S. FDA, will be tasked with maintaining the agency's gold ...
The National Childhood Vaccine Injury Act of 1986 removed the economic incentive that held vaccine developers accountable for vaccine safety. Reforms, including properly designed trials, are needed to ...
The Company now also plans to submit a label extension application to the UK MHRA. Valneva is focused on expanding the vaccine’s label and access. In the third quarter of 2024, the Company expanded ...
The Department of Health and Human Services, headed by RFK Jr., is responding to reports that the CDC will begin researching ...
Plaintiffs argued Merck should have added warnings to labels for Gardasil about the risk of heart rate increases and ovarian problems allegedly associated with the vaccine. But the judge said federal ...
Valneva is focused on expanding the vaccine’s label and access. In the third quarter of 2024, the Company expanded its partnership with CEPI12, with support from the EU Horizon Europe program ...
If granted, IXCHIQ ® will become the first vaccine against the chikungunya virus ... and a decision on the label extension application of IXCHIQ ® in the European Union (EU), Norway ...
Valneva is focused on expanding the vaccine's label and access. In the third quarter of 2024, the Company expanded its partnership with CEPI 12, with support from the EU Horizon Europe program, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results